I-MAB Releases Promising Phase I Data for Givastomig in Advanced Gastric Cancer

I-MAB ( (IMAB) ) just unveiled an announcement.

I-MAB has released updated data from its Phase I study of Givastomig, a novel bispecific antibody targeting Claudin 18.2, in patients with advanced gastroesophageal carcinoma. The study, which included patients from the US and China, demonstrated that Givastomig was well-tolerated and showed promising efficacy, with no dose-limiting toxicities observed up to 18 mg/kg. The findings suggest potential for Givastomig in treating heavily pretreated gastric cancer patients, which could enhance I-MAB’s positioning in the oncology market.

The most recent analyst rating on (IMAB) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.

Spark’s Take on IMAB Stock

According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on IMAB stock, click here.

More about I-MAB

I-MAB is a biopharmaceutical company focused on the development of novel or highly differentiated biologics, particularly in the field of immuno-oncology. The company is engaged in the research and development of innovative therapies for cancer treatment, with a focus on the global market.

Average Trading Volume: 2,680,252

Technical Sentiment Signal: Buy

Current Market Cap: $381.7M

Find detailed analytics on IMAB stock on TipRanks’ Stock Analysis page.